Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
GLYC's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. GLYC: No Debt )
GLYC' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Interest Coverage No Debt
GLYC's Interest Coverage is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. GLYC: No Debt )
GLYC' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

Z-Score: 42.90
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -265.19
GLYC's Operating margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. GLYC: -265.19 )
GLYC' s 10-Year Operating margin (%) Range
Min: -265.19   Max: 24
Current: -265.19

-265.19
24
Net-margin (%) -265.61
GLYC's Net-margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. GLYC: -265.61 )
GLYC' s 10-Year Net-margin (%) Range
Min: -265.61   Max: 23.96
Current: -265.61

-265.61
23.96
ROE (%) -364.84
GLYC's ROE (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. GLYC: -364.84 )
GLYC' s 10-Year ROE (%) Range
Min: -364.84   Max: 29.18
Current: -364.84

-364.84
29.18
ROA (%) -200.76
GLYC's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. GLYC: -200.76 )
GLYC' s 10-Year ROA (%) Range
Min: -200.76   Max: 19.85
Current: -200.76

-200.76
19.85
ROC (Joel Greenblatt) (%) -1525.79
GLYC's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. GLYC: -1525.79 )
GLYC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2589.36   Max: 811.97
Current: -1525.79

-2589.36
811.97
» GLYC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

GLYC Guru Trades in

GLYC Guru Trades in

GLYC Guru Trades in

Q1 2014

GLYC Guru Trades in Q1 2014

Steven Cohen 28,648 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with GLYC



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.00
GLYC's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. GLYC: 3.00 )
GLYC' s 10-Year P/B Range
Min: 0   Max: 6.4
Current: 3

0
6.4
P/S 252.40
GLYC's P/S is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. GLYC: 252.40 )
GLYC' s 10-Year P/S Range
Min: 0   Max: 271.6
Current: 252.4

0
271.6
EV-to-EBIT 18.50
GLYC's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. GLYC: 18.50 )
GLYC' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 18.5

Current Ratio 21.83
GLYC's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. GLYC: 21.83 )
GLYC' s 10-Year Current Ratio Range
Min: 2.14   Max: 21.83
Current: 21.83

2.14
21.83
Quick Ratio 21.83
GLYC's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. GLYC: 21.83 )
GLYC' s 10-Year Quick Ratio Range
Min: 2.14   Max: 21.83
Current: 21.83

2.14
21.83

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.00
GLYC's Price/Net Cash is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. GLYC: 3.00 )
GLYC' s 10-Year Price/Net Cash Range
Min: 0   Max: 0
Current: 3

Price/Net Current Asset Value 3.00
GLYC's Price/Net Current Asset Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. GLYC: 3.00 )
GLYC' s 10-Year Price/Net Current Asset Value Range
Min: 0   Max: 0
Current: 3

Price/Tangible Book 2.90
GLYC's Price/Tangible Book is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. GLYC: 2.90 )
GLYC' s 10-Year Price/Tangible Book Range
Min: 0   Max: 0
Current: 2.9

Business Description

Industry: »
Compare: » details
Traded in other countries:GKO.Germany
» More Articles for GLYC

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Nasdaq stocks posting largest percentage increases Jul 23 2014
GLYCOMIMETICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD... Jul 10 2014
GlycoMimetics Appoints Mark A. Goldberg, M.D. to Board of Directors Jul 10 2014
GlycoMimetics Up on FDA Agreement on Rivipansel Study Jul 02 2014
GlycoMimetics to Present at Jefferies Healthcare Conference May 28 2014
Options For Pfizer Investors May 22 2014
GlycoMimetics receives $15M payment from Pfizer related to rivipansel May 20 2014
GlycoMimetics Receives $15 Million Payment from Pfizer in Connection with Planned Initiation of... May 20 2014
GLYCOMIMETICS INC Financials May 16 2014
GlycoMimetics announces presentation of GMI-1070 data May 15 2014
GlycoMimetics Announces Presentation of Rivipansel Data in Pediatric Patients at American Society of... May 15 2014
GLYCOMIMETICS INC Files SEC form 10-Q, Quarterly Report May 09 2014
GLYCOMIMETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 08 2014
GlycoMimetics Reports First Quarter 2014 Results May 08 2014
Should GlycoMimetics (GLYC) Be On Your Radar Now? Apr 29 2014
GlycoMimetics Appoints Seasoned Business Development Executive Armand Girard as New Vice President,... Apr 23 2014
GlycoMimetics presents GMI-1070 data Apr 14 2014
GlycoMimetics Announces Presentation of Data on Rivipansel (GMI-1070) in Combination with Current... Apr 14 2014
How GlycoMimetics (GLYC) Stock Stands Out in a Strong Industry Apr 11 2014
GlycoMimetics: A Promising Sickle Cell Disease Play Apr 10 2014
GlycoMimetics Presents Data on Its E-Selectin Antagonist at American Association for Cancer Research... Apr 09 2014
GLYCOMIMETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in... Apr 04 2014
Why GlycoMimetics (GLYC) Could Be Positioned for a Surge? Apr 04 2014
GlycoMimetics Announces Pricing of Initial Public Offering Jan 09 2014
GlycoMimetics Shares Progress with Novel E-selectin Antagonist Drug Candidate at 2013 American... Dec 09 2013
GlycoMimetics to Present Five Abstracts at 2013 American Society of Hematology Annual Meeting Nov 11 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide